Ultragenyx Reports Topline Cohort 2 Results From Phase 1/2 Study Of DTX301 In Ornithine Transcarbamylase Deficiency: Normalized 1 Patient In Cohort, Responder Showed 'continued biochemical improvement and clinical stability at Week 52'